Company / Return on Equity (ROE)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Return on Equity (ROE) History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-61.2%
FY2024
5-year range
-61.2% / -22.9%
FY2020-FY2024
Trend
-39.8%
vs FY2023
Sector context
#142 of 148
Health Care
What the data says
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reports negative total equity of -61.2% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-61.2% in FY2024 with a 5-year CAGR of +92.0%.
Declined from -55.8% to -61.2% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -38.3pp
- 5-Year Change
- +92.0pp
- 10-Year Change
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 148This company -61.2% Sector average -3.2%
▼
-1836.5% below sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) decreased 39.8% year-over-year.
- Currently 58.0pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2020.
- Lowest return on equity (roe) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -61.2% | -39.8% |
| FY2023 | -43.7% | +21.7% |
| FY2022 | -55.8% | -143.7% |
| FY2021 | -22.9% | -361.5% |
| FY2020 | 8.8% | +105.7% |
| FY2019 | -153.2% | -70.4% |
| FY2018 | -89.9% | +16.0% |
| FY2017 | -107.1% | -21.9% |
| FY2016 | -87.8% | +23.4% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026